Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 18/20 | 0.71 |
| ▸ | FLT3 | P36888 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 2/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | JAK3 | P52333 | 1/20 | 0.56 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.56 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL136163 | 0.83 | PIM1 (1.00) | PIM1KCNH2 | |
| SCHEMBL136164 | 0.83 | PIM1 (1.00) | PIM1KCNH2 | |
| SCHEMBL14422681 | 0.82 | PIM1 (1.00) | PIM1FLT3GSK3BJAK2CDK2 | |
| SCHEMBL14653621 | 0.80 | PIM1 (1.00) | PIM1 | |
| SCHEMBL22837207 | 0.80 | PIM1 (1.00) | PIM1 | |
| SCHEMBL14422665 | 0.78 | PIM1 (1.00) | PIM1FLT3GSK3BJAK2CDK2 | |
| SCHEMBL5618964 | 0.78 | PIM1 (0.92) | PIM1FLT3GSK3BJAK2CDK2 | |
| SCHEMBL14422647 | 0.77 | PIM1 (1.00) | PIM1FLT3GSK3BJAK2CDK2 | |
| SCHEMBL14422660 | 0.75 | PIM1 (1.00) | PIM1FLT3GSK3BJAK2CDK2 | |
| SCHEMBL14422676 | 0.74 | PIM1 (1.00) | PIM1FLT3GSK3BJAK2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238183-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238183-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM1 1/4885FLT3 120/4885GSK3B 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.